Investigating what deserves attention.

Why perfume makers are studying weight-loss drug users

IFF and Givaudan report signs of greater interest in fragrance among GLP-1 users. Whether that extends to perfumes evoking cake and vanilla remains an open question.

Published

Fragrance makers IFF and Givaudan are investigating whether people taking GLP-1 medicines, used for weight loss, become more interested in perfume. IFF told Reuters that its research suggested these users may seek more sensory pleasure from scent. Givaudan said it had observed an overall increase in their interest in fragrance. Reuters (source, opens in new tab)

Givaudan also said it was expanding its gourmand perfumes: fragrances that evoke food, including cake and vanilla. Its observation about GLP-1 users concerns fragrance overall, however, rather than a demonstrated preference for these food-inspired scents.

The public reporting provides no methods, sample sizes or detailed results for the company research. It therefore offers an early account of what fragrance businesses are exploring, without establishing that the medicines cause a change in scent preferences.